70 related articles for article (PubMed ID: 15249719)
21. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma.
Kato H; Kuwano H; Nakajima M; Miyazaki T; Yoshikawa M; Ojima H; Tsukada K; Oriuchi N; Inoue T; Endo K
Cancer; 2002 Feb; 94(4):921-8. PubMed ID: 11920459
[TBL] [Abstract][Full Text] [Related]
22. [18FDG-PET imaging of pancreatic adenocarcinoma].
Daenen F; Hustinx R; Belhocine T; Focan C; Honoré P; Rigo P
Rev Med Liege; 2000 Feb; 55(2):89-94. PubMed ID: 10769575
[TBL] [Abstract][Full Text] [Related]
23. Nonfunctioning endocrine pancreatic tumor examined with 18F-FDG PET/CT.
Toshikuni N; Kai K; Fujisawa M
Ann Nucl Med; 2008 Feb; 22(2):133-7. PubMed ID: 18311538
[TBL] [Abstract][Full Text] [Related]
24. Clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the management of patients with nonpancreatic periampullary neoplasms.
Sperti C; Pasquali C; Fiore V; Bissoli S; Chierichetti F; Liessi G; Pedrazzoli S
Am J Surg; 2006 Jun; 191(6):743-8. PubMed ID: 16720142
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
[TBL] [Abstract][Full Text] [Related]
26. [The role of FDG-PET scan in the diagnosis of pancreatic carcinoma].
Papós M; Takács T; Pávics L; Farkas G; Ambrus E; Szakáll S; Lonovics J; Csernay L; Trón L
Orv Hetil; 2002 May; 143(21 Suppl 3):1283-6. PubMed ID: 12077917
[TBL] [Abstract][Full Text] [Related]
27. Value of 18-F-deoxyglucose (FDG) positron emission tomography (PET) for the diagnosis of pancreatic cancer.
Buell U; Zimmy M
World J Surg; 2003 Apr; 27(4):499; author reply 499-500. PubMed ID: 12658505
[No Abstract] [Full Text] [Related]
28. [Correlation of FDG-PET and MRI/CT with histopathology in primary diagnosis, lymph node staging and diagnosis of recurrency of head and neck cancer].
Pöpperl G; Lang S; Dagdelen O; Jäger L; Tiling R; Hahn K; Tatsch K
Rofo; 2002 Jun; 174(6):714-20. PubMed ID: 12063600
[TBL] [Abstract][Full Text] [Related]
29. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
[TBL] [Abstract][Full Text] [Related]
30. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study.
Katsoulis IE; Wong WL; Mattheou AK; Damani N; Chambers J; Livingstone JI
Int J Surg; 2007 Dec; 5(6):399-403. PubMed ID: 17631431
[TBL] [Abstract][Full Text] [Related]
31. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
[TBL] [Abstract][Full Text] [Related]
32. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography with 2-deoxy-2-[(18)F] fluoro- d-glucose for diagnosis of intraductal papillary mucinous tumor of the pancreas with parenchymal invasion.
Yoshioka M; Sato T; Furuya T; Shibata S; Andoh H; Asanuma Y; Hatazawa J; Koyama K
J Gastroenterol; 2003; 38(12):1189-93. PubMed ID: 14714260
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
35. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?
Buck AC; Schirrmeister HH; Guhlmann CA; Diederichs CG; Shen C; Buchmann I; Kotzerke J; Birk D; Mattfeldt T; Reske SN
J Nucl Med; 2001 May; 42(5):721-5. PubMed ID: 11337566
[TBL] [Abstract][Full Text] [Related]
36. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
[TBL] [Abstract][Full Text] [Related]
37. [The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions].
Voth M; Opfermann T; Gottschild D
Zentralbl Chir; 2003 May; 128(5):375-8. PubMed ID: 12813634
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography in colorectal cancer.
Flamen P
Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):237-51. PubMed ID: 11969236
[TBL] [Abstract][Full Text] [Related]
39. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
40. Value of positron emission tomography for lung cancer staging.
Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]